Avro Life Science’s pipeline is focused on improving patient outcomes and quality of life by delivering high-value medication through the skin.
Avro’s passive topical delivery platform serves to redefine the skin’s potential as a therapeutic vector, enabling the systemic delivery of small molecules and peptides, and the localized delivery of larger, complex therapeutics, including proteins, antibodies, nucleic acids, CRISPR, and more into the skin, without the use of microneedles or other invasive technology.
Avro’s vision is to enhance the delivery of a range of existing therapeutics, while unlocking the potential of the next generation of dermal therapies and novel modalities in the same way that lipid nanoparticle technology unlocked the potential of mRNA vaccines.
Our systemic drug delivery portfolio focuses on translating non-orally available small molecules and peptides (often delivered subcutaneously/intravenously) into 1-7 day use transdermal patches (dose-dependent). Current programs in PD and ALS address neurologically and/or motor-compromised elderly populations which are underserved by today’s invasive and inaccessible delivery methods.
Our topical drug delivery portfolio serves to enable the in-situ dermal delivery of novel therapeutic modalities like nucleic acid therapeutics (ASOs, siRNAs, mRNAs, CRISPR-RNPs) for gene editing and therapy in the skin, with curative intent. Our topical platform also enables the targeted delivery of biologics like proteins and antibodies for localized therapeutic effects with reduced side effect profiles and higher site-specific efficacy.
Our NCE portfolio utilises PEGylated small molecules and novel targets (TrkA) to address some of the most prevalent inflammatory skin conditions such aspsoriasis, and atopic dermatitis.
Avro is a leading preclinical stage pharmaceutical company developing OmniDerm(™)
a platform transdermal technology for the passive delivery of small drug molecules.
Avro’s novel polymer utilizes cutting-edge advances in biomaterials engineering and micro-encapsulation technology, to hold and deliver a wide range of drugs over a 1-7 day timespan, where transdermal delivery was previously thought to be impossible.
Our mission is to improve patient health outcomes and quality of life through medication compliance and adherence afforded by effective drug delivery solutions.
To learn more, or chat about partnering, send us a note at: firstname.lastname@example.org
One-size-fits-all versatile platform allowing for encapsulation and delivery of a wide variety of different small molecule drugs, inplace of existing “lock and key” patches available on the market, requiring a custom polymer for each drug.
Cost-effective, tunable, and easily scalable manufacturing processes using easily sourced and non-irritant, non-toxic materials and known industrial methods. Results in a single layer, drug-in-adhesive, sweatproof, waterproof, non-irritant patch with few failure modes during production due to the polymer’s fundamental chemistry.
Relies on fundamental materials science breakthroughs enabled by recent advances in understanding of biomaterial interactions and microencapsulation methods. Eliminates the need for expensive microneedles, lock and key patches, and complex manufacturing processes, allowing Avro to succeed where pharma has failed